The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
暂无分享,去创建一个
M. Colado | A. Richard Green | Annis O. Mechan | J. Martin Elliott | Esther O'Shea | M. Isabel Colado | E. O'Shea | A. Mechan | J. Elliott | A. Green
[1] A. Cho,et al. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. , 1990, The Journal of pharmacology and experimental therapeutics.
[2] J. Docherty,et al. Prejunctional actions of methylenedioxymethamphetamine in vas deferens from wild-type and alpha(2A/D)-adrenoceptor knockout mice. , 2001, European journal of pharmacology.
[3] J. Galbete,et al. Methylenedioxymethamphetamine induces opposite changes in central pre- and postsynaptic 5-HT1A receptors in rats. , 1995, European journal of pharmacology.
[4] D. E. Nichols,et al. Effect of the R(−) and S(+) isomers of MDA and MDMA on phosphotidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors , 1994, Neuroscience Letters.
[5] U. McCann,et al. Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity , 2002, Journal of neurochemistry.
[6] M. Ingelman-Sundberg,et al. Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. , 1991, Free radical biology & medicine.
[7] P. Kelly,et al. EVIDENCE CONCERNING THE INVOLVEMENT OF 5‐HYDROXYTRYPTAMINE IN THE LOCOMOTOR ACTIVITY PRODUCED BY AMPHETAMINE OR TRANYLCYPROMINE PLUS l‐DOPA , 1976, British journal of pharmacology.
[8] Charles V. Vorhees,et al. 3,4-Methylenedioxymethamphetamine (Ecstasy)-Induced Learning and Memory Impairments Depend on the Age of Exposure during Early Development , 2001, The Journal of Neuroscience.
[9] F. Vollenweider,et al. Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers , 1998, Neuropsychopharmacology.
[10] A. Cho,et al. Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. , 1992, Chemical research in toxicology.
[11] F. Vollenweider,et al. Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram , 1999, Neuropsychopharmacology.
[12] G. Hanson,et al. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. , 2002, The Journal of pharmacology and experimental therapeutics.
[13] R. Hen,et al. Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor , 1999, Psychopharmacology.
[14] D. Charney,et al. Serotonergic function in depression. Prolactin response to intravenous tryptophan in depressed patients and healthy subjects. , 1984, Archives of general psychiatry.
[15] M. Colado,et al. Role of hyperthermia in the protective action of clomethiazole against MDMA (‘ecstasy’)‐induced neurodegeneration, comparison with the novel NMDA channel blocker AR‐R15896AR , 1998, British journal of pharmacology.
[16] G. Hanson,et al. Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine. , 1992, The Journal of pharmacology and experimental therapeutics.
[17] B. Logan,et al. Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. , 1988, European journal of pharmacology.
[18] V. Sánchez,et al. Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats , 2003, Neuropharmacology.
[19] A. Young,et al. A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field , 2002, Psychopharmacology.
[20] E. London,et al. Effects of methylenedioxymethamphetamine on local cerebral glucose utilization in the rat , 1989, Neuropharmacology.
[21] C. Vorhees,et al. Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine , 2001, Psychopharmacology.
[22] Long-term partial 5-HT depletion: interference of anxiety and impulsivity? , 2002, Psychopharmacology.
[23] T. Insel,et al. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. , 1989, The Journal of pharmacology and experimental therapeutics.
[24] M. Shannon. Methylenedioxymethamphetamine (MDMA, "Ecstasy"). , 2000, Pediatric emergency care.
[25] M. Gobbi,et al. Carrier‐dependent and Ca2+‐dependent 5‐HT and dopamine release induced by (+)‐amphetamine, 3,4‐methylendioxy‐methamphetamine, p‐chloroamphetamine and (+)‐fenfluramine , 1997, British journal of pharmacology.
[26] J. Rodgers,et al. Cognitive performance amongst recreational users of "ecstasy , 2000, Psychopharmacology.
[27] H. Wolf,et al. Hyperthermia and the amphetamine aggregation phenomenon: Absence of a causal relation , 1973, The Journal of pharmacy and pharmacology.
[28] W. Slikker,et al. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. , 1989, Neurotoxicology.
[29] G. Ricaurte,et al. Long‐term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine , 2001, Synapse.
[30] J. Vissing,et al. Exercise-Induced Changes in Local Cerebral Glucose Utilization in the Rat , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] M. Molliver,et al. Microglial response to degeneration of serotonergic axon terminals , 1994, Glia.
[32] M. Wilson,et al. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. , 1988, JAMA.
[33] G. Tucker,et al. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). , 1994, Biochemical pharmacology.
[34] J. del Río,et al. The role of dopaminergic systems in the perinatal sensitivity to 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in rats. , 1998, The Journal of pharmacology and experimental therapeutics.
[35] W. Slikker,et al. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate , 1991, Pharmacology Biochemistry and Behavior.
[36] J. O'Callaghan,et al. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat , 1991, Pharmacology Biochemistry and Behavior.
[37] G. Koob,et al. A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA , 2004, Psychopharmacology.
[38] H. Kupferberg,et al. Hyperthermia in d-amphetamine toxicity in aggregated mice of different strains. , 1972, The Journal of pharmacology and experimental therapeutics.
[39] M. Colado,et al. In vivo evidence against clomethiazole being neuroprotective against MDMA (‘ecstasy’)-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism , 1999, Neuropharmacology.
[40] E. Gordon-Smith,et al. Aplastic anaemia following exposure to 3,4‐methylenedioxymethamphetamine (‘Ecstasy’) , 1994, British journal of haematology.
[41] J. Merrill. Ecstasy and neurodegeneration , 1996, BMJ.
[42] M. Dragunow,et al. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. , 1995, Pharmacological reviews.
[43] G. Hanson,et al. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. , 1986, European journal of pharmacology.
[44] B. Stimmel,et al. The Love Drug: Marching to the Beat of Ecstasy , 1998 .
[45] A. R. Green,et al. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (‘Ecstasy’) to rats , 1994, Neuropharmacology.
[46] A. Parrott,et al. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug , 2001, Journal of psychopharmacology.
[47] D. Epstein,et al. The action of some amines related to adrenaline , 1932, Journal of Physiology.
[48] N. Thiriet,et al. Involvement of free radicals in MDMA-induced neurotoxicity in mice. , 2001, Annales de medecine interne.
[49] J. Docherty,et al. Investigation of the prejunctional α2‐adrenoceptor mediated actions of MDMA in rat atrium and vas deferens , 1999 .
[50] J. O'Callaghan,et al. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. , 1994, The Journal of pharmacology and experimental therapeutics.
[51] T. Chiba,et al. Analgesic effect of intrathecally administered orexin‐A in the rat formalin test and in the rat hot plate test , 2002, British journal of pharmacology.
[52] C. J. Schmidt. Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. , 1987, European journal of pharmacology.
[53] W. Streit,et al. Loss of serotonin uptake sites and immunoreactivity in rat cortex after dexfenfluramine occur without parallel glial cell reactions , 1993, Brain Research.
[54] C. J. Schmidt,et al. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. , 1990, The Journal of pharmacology and experimental therapeutics.
[55] Y. Oomura,et al. In vivo measurement of hypothalamic serotonin release by intracerebral microdialysis: Significant enhancement by immobilization stress in rats , 1992, Brain Research Bulletin.
[56] M. Colado,et al. The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. , 1995, European journal of pharmacology.
[57] M. Colado,et al. Studies on the role of dopamine in the degeneration of 5‐HT nerve endings in the brain of Dark Agouti rats following 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration , 1999, British journal of pharmacology.
[58] J. Henry. Ecstasy and the dance of death. , 1992, BMJ.
[59] R. Glennon,et al. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis , 1989, Psychopharmacology.
[60] Syed F. Ali,et al. nNOS inhibitors attenuate methamphetamine‐induced dopaminergic neurotoxicity but not hyperthermia in mice , 2000, Neuroreport.
[61] R. Glennon,et al. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors , 1998, Psychopharmacology.
[62] J. Bakalar,et al. Can drugs be used to enhance the psychotherapeutic process? , 1986, American journal of psychotherapy.
[63] D. Grahame-Smith,et al. Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by l‐tryptophan or 5‐methoxy‐N,N‐dimethyltryptamine in rats treated with a monoamine oxidase inhibitor , 1971, British journal of pharmacology.
[64] M. Galloway,et al. MDMA induced dopamine release in vivo: role of endogenous serotonin , 2005, Journal of Neural Transmission.
[65] M. Shankaran,et al. 3,4-Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. , 2002, The Journal of pharmacology and experimental therapeutics.
[66] C. J. Schmidt,et al. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. , 1987, Biochemical pharmacology.
[67] G. Gudelsky. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin , 2005, Journal of Neural Transmission.
[68] T. Steele,et al. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. , 1987, Biochemical pharmacology.
[69] P. Huang,et al. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. , 1998, The Journal of pharmacology and experimental therapeutics.
[70] V. Sánchez,et al. A study of the mechanisms involved in the neurotoxic action of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain , 2001, British journal of pharmacology.
[71] A. Milton. The hypothalamus and the pharmacology of thermoregulation , 1978 .
[72] Y. Shaham,et al. Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans , 1994, Neuropsychopharmacology.
[73] D. Nichols,et al. An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA , 2002, Pharmacology, Biochemistry and Behavior.
[74] H. J. Olverman,et al. Functional consequences of perinatal exposure to3,4‐methylenedioxymethamphetamine in rat brain , 2002, British journal of pharmacology.
[75] M. Colado,et al. A study of the neurotoxic effect of MDMA (‘ecstasy’) on 5‐HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy , 1997, British journal of pharmacology.
[76] M. Morgan. Memory deficits associated with recreational use of “ecstasy” (MDMA) , 1999, Psychopharmacology.
[77] U. McCann,et al. Caveat Emptor: Editors Beware , 2001, Neuropsychopharmacology.
[78] U. McCann,et al. Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA ("Ecstasy") , 2002, Science.
[79] A. Young,et al. A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam , 2002, Psychopharmacology.
[80] J. V. van Gerven,et al. Cognitive performance and serotonergic function in users of ecstasy , 2000, Psychopharmacology.
[81] G. Goodwin,et al. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) , 1995, Psychopharmacology.
[82] J. Nash. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. , 1990, Life sciences.
[83] M. Colado,et al. The spin trap reagent PBN attenuates degeneration of 5-HT neurones in rat brain induced by p-chloroamphetamine but not fenfluramine , 1996, Neuropharmacology.
[84] A. R. Green,et al. Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine , 1976, Nature.
[85] H. Meltzer,et al. Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men , 1995, Biological Psychiatry.
[86] Bill Bynum,et al. Ecstasy , 2003, The Lancet.
[87] R. Foltz,et al. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. , 1988, Chemical research in toxicology.
[88] D. Murphy,et al. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users , 1999, Psychopharmacology.
[89] M. P. Johnson,et al. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. , 1986, European journal of pharmacology.
[90] B. Lin,et al. Detection of Free Radical Activity During Transient Global Ischemia and Recirculation: Effects of Intraischemic Brain Temperature Modulation , 1995, Journal of neurochemistry.
[91] H. D. Abraham,et al. The Psychopharmacology of Hallucinogens , 1996, Neuropsychopharmacology.
[92] R. Zaczek,et al. Intrasynaptosomal Sequestration of [3H]Amphetamine and [3H]Methylenedioxyamphetamine: Characterization Suggests the Presence of a Factor Responsible for Maintaining Sequestration , 1990, Journal of neurochemistry.
[93] G. Hanson,et al. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. , 1988, The Journal of pharmacology and experimental therapeutics.
[94] J. Brodkin,et al. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. , 1991, The Journal of pharmacology and experimental therapeutics.
[95] F. Vollenweider,et al. 3,4-Methylenedioxymethamphetamine (MDMA) Modulates Cortical and Limbic Brain Activity as Measured by [H215O]-PET in Healthy Humans , 2000, Neuropsychopharmacology.
[96] L. Seiden,et al. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. , 1995, The Journal of pharmacology and experimental therapeutics.
[97] A. Parrott,et al. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance , 1998, Psychopharmacology.
[98] A. Weil. The Love Drug , 1976 .
[99] E. D. De Souza,et al. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. , 1988, European journal of pharmacology.
[100] A. Morton,et al. Methamphetamine toxicity in mice is potentiated by exposure to loud music , 2001, Neuroreport.
[101] S. Yamawaki,et al. Dopaminergic and serotonergic mechanisms of thermoregulation: mediation of thermal effects of apomorphine and dopamine. , 1983, The Journal of pharmacology and experimental therapeutics.
[102] Liesbeth Reneman,et al. Validity of [123I]β‐CIT SPECT in detecting MDMA‐induced serotonergic neurotoxicity , 2002, Synapse.
[103] C. J. Schmidt,et al. Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. , 1988, European journal of pharmacology.
[104] D. Cannon,et al. In vitro neuronal and vascular responses to 5‐HT in rats chronically exposed to MDMA , 2001, British journal of pharmacology.
[105] R. Strassman,et al. Information on "Ecstasy". , 2006, The American journal of psychiatry.
[106] L. Seiden,et al. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. , 1985, Science.
[107] Syed F. Ali,et al. Effects of 7‐Nitroindazole, an NOS Inhibitor on Methamphetamine‐Induced Dopaminergic and Serotonergic Neurotoxicity in Mice a , 1998, Annals of the New York Academy of Sciences.
[108] J. Krystal,et al. Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations. , 1989, Archives of general psychiatry.
[109] S. Kish,et al. Brief Communications Expedited Publication Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user , 2000 .
[110] G. D. den Heeten,et al. MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. , 2000, AJNR. American journal of neuroradiology.
[111] J. Langston,et al. Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions , 1994, Annals of neurology.
[112] G. M. Goodwin,et al. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5‐HT1 and 5‐HT2 receptors , 1985, British journal of pharmacology.
[113] H. Meltzer,et al. Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men , 1995, Psychiatry Research.
[114] L. Seiden,et al. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. , 1996, The Journal of pharmacology and experimental therapeutics.
[115] M. Wilson,et al. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine , 1989, Neuroscience.
[116] T. Heffernan,et al. Prospective memory, everyday cognitive failure and central executive function in recreational users of Ecstasy , 2001, Human psychopharmacology.
[117] S. Yeh,et al. The neurochemical and stimulatory effects of putative metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in rats , 1991, Pharmacology Biochemistry and Behavior.
[118] M. Mardini. Ear-clicking "tinnitus" responding to carbamazepine. , 1987, The New England journal of medicine.
[119] W. van den Brink,et al. Memory disturbances in ”Ecstasy” users are correlated with an altered brain serotonin neurotransmission , 2000, Psychopharmacology.
[120] M. Forsling,et al. The effect of 3,4‐methylenedioxymethamphetamine (MDMA, ?ecstasy?) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus , 2002, British journal of pharmacology.
[121] V. Sánchez,et al. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose , 2001, Psychopharmacology.
[122] L. Manzino,et al. Unexpected differences between mazindol and its homologs on biochemical and behavioral responses. , 1981, The Journal of pharmacology and experimental therapeutics.
[123] J. Kelly,et al. Acute 3,4-methylenedioxymethamphetamine(MDMA) administration produces a rapid and sustained suppression of immune function in the rat. , 1998, Immunopharmacology.
[124] G. Ricaurte,et al. Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors , 1992, Neuropharmacology.
[125] J. Mendelson,et al. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans , 2002, Psychopharmacology.
[126] G. Screaton,et al. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse , 1992, The Lancet.
[127] F. Vollenweider,et al. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers , 2000, Journal of psychopharmacology.
[128] C. J. Schmidt,et al. 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. , 1991, The Journal of pharmacology and experimental therapeutics.
[129] C. J. Schmidt,et al. Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors , 1990, Brain Research.
[130] J. Fozard,et al. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. , 1984, European journal of pharmacology.
[131] B. Logan,et al. 3,4-Methylenedioxymethamphetamine induces Fos-like proteins in rat basal ganglia: reversal with MK 801. , 1991, European journal of pharmacology.
[132] J. Kelly,et al. An appraisal of the pharmacological and toxicological effects of a single oral administration of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. , 1997, Pharmacology & toxicology.
[133] T. Ullrich,et al. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement , 2002, Psychopharmacology.
[134] P. Lomax,et al. Body temperature : regulation, drug effects, and therapeutic implications , 1979 .
[135] B. Halliwell,et al. Hydroxylation of salicylate and phenylalanine as assays for hydroxyl radicals: a cautionary note visited for the third time. , 1997, Free radical research.
[136] A. Cho,et al. Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. , 1994, Molecular pharmacology.
[137] G. Ricaurte,et al. Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine]. , 1992, Chemical research in toxicology.
[138] R. Leslie,et al. P-chloroamphetamine induces C-fos in rat brain: A study of serotonin2A/2C receptor function , 1996, Neuroscience.
[139] J. Langston,et al. Orally administered MDMA causes a long-term depletion of serotonin in rat brain , 1988, Brain Research.
[140] G. T. Taylor,et al. ‘Ecstasy’ Ingestion: A Case Report of Severe Complications , 1993, Journal of the Royal Society of Medicine.
[141] V. Curran,et al. Sub-acute effects of MDMA (±3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences , 2002, Psychopharmacology.
[142] J. Fitzgerald,et al. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.
[143] A. Weston,et al. Pharmacology of the Hypothalamus , 1978, Palgrave Macmillan UK.
[144] M. Christie,et al. The Anxiogenic-Like and Anxiolytic-Like Effects of MDMA on Mice in the Elevated Plus-Maze A Comparison With Amphetamine , 1999, Pharmacology Biochemistry and Behavior.
[145] J. Richards,et al. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. , 1996, The Journal of pharmacology and experimental therapeutics.
[146] E. Azmitia,et al. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. , 1992, European journal of pharmacology.
[147] K. Cunningham,et al. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. , 1999, The Journal of pharmacology and experimental therapeutics.
[148] Myers Rd. Serotonin and thermoregulation: old and new views. , 1981 .
[149] K. Cunningham,et al. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA) , 1992, Brain Research Bulletin.
[150] M. Piercey,et al. Effects of MDMA (‘ecstasy’) on firing rates of serotonergic, dopaminergic, and noradrenergic neurons in the rat , 1990, Brain Research.
[151] G. Bonvento,et al. SEROTONIN IN THE REGULATION OF BRAIN MICROCIRCULATION , 1996, Progress in Neurobiology.
[152] L. Fogelson,et al. Metabolic and thermoregulatory responses of the rat maintained in acrylic or wire-screen cages: Implications for pharmacological studies , 1994, Physiology & Behavior.
[153] D. Braida,et al. Role of the endocannabinoid system in MDMA intracerebral self‐administration in rats , 2002, British journal of pharmacology.
[154] B. Yamamoto,et al. Ascorbic acid prevents 3,4‐methylenedioxymethamphetamine (MDMA)‐induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5‐HT , 2001, Synapse.
[155] U. McCann,et al. Memory impairment in abstinent MDMA ("Ecstasy") users , 1998, Neurology.
[156] R T GRANT,et al. Vasodilatation and body warming in the rat , 1963, The Journal of physiology.
[157] Aronson Ta,et al. Ecstasy" (MDMA)-induced panic. , 1989 .
[158] M. Colado,et al. The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype , 1995, British journal of pharmacology.
[159] U. McCann,et al. Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study , 1999, Psychopharmacology.
[160] M. Spedding,et al. Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA‐, α1‐ and 5‐HT2A‐receptors , 2002, British journal of pharmacology.
[161] C. Schmidt,et al. Effects of the Selective 5-HT2A Receptor Antagonist MDL 100,907 on MDMA-Induced Locomotor Stimulation in Rats , 1996, Neuropsychopharmacology.
[162] J. Fitzgerald,et al. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. , 1990, European journal of pharmacology.
[163] Evidence that m-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT 2 c receptors , 2022 .
[164] I. McGregor,et al. The distribution of 3,4-methylenedioxymethamphetamine “Ecstasy”-induced c-fos expression in rat brain , 1999, Neuroscience.
[165] P. Salmi,et al. Evidence for functional interactions between 5-HT1A and 5-HT2A receptors in rat thermoregulatory mechanisms. , 1998, Pharmacology & toxicology.
[166] W. Schmidt,et al. Changes in serotonin, dopamine and noradrenaline levels in striatum and nucleus accumbens after repeated administration of the abused drug MDMA in rats , 2001, Neuroscience Letters.
[167] A. Parrott,et al. Ecstasy (MDMA), amphetamine, and LSD: comparative mood profiles in recreational polydrug users , 1997 .
[168] P. Jones,et al. Psychiatric symptoms in cannabis users , 1993, British Journal of Psychiatry.
[169] H. Meltzer,et al. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. , 1988, The Journal of pharmacology and experimental therapeutics.
[170] W. Slikker,et al. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. , 1995, The Journal of pharmacology and experimental therapeutics.
[171] J. Swettenham,et al. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity , 2002, Psychopharmacology.
[172] J. Osterloh,et al. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy') , 1987, JAMA.
[173] D. Grandy,et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. , 2001, Molecular pharmacology.
[174] D E Nichols,et al. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. , 1998, Neurotoxicology.
[175] D. Murphy,et al. Evidence thatm-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2C receptors , 1996, Psychopharmacology.
[176] S. Imam,et al. Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic toxicity and peroxynitrite generation , 2000, Brain Research.
[177] A. Poling,et al. MDMA and Learning Effects of Acute and Neurotoxic Exposure in the Rat , 2000, Pharmacology Biochemistry and Behavior.
[178] A S Christophersen,et al. Amphetamine designer drugs - an overview and epidemiology. , 2000, Toxicology letters.
[179] V. Sánchez,et al. Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4‐methylenedioxymethamphetamine (‘ecstasy’)‐induced dopamine release and free radical formation in the mouse striatum , 2002, Journal of neurochemistry.
[180] M. Geyer,et al. Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice , 2000, Neuropharmacology.
[181] V. Sánchez,et al. The mechanisms involved in the long‐lasting neuroprotective effect of fluoxetine against MDMA (‘ecstasy’)‐induced degeneration of 5‐HT nerve endings in rat brain , 2001, British journal of pharmacology.
[182] M. Chance. Factors influencing the toxicity of sympathomimetic amines to solitary mice. , 1947, The Journal of pharmacology and experimental therapeutics.
[183] J. Langston,et al. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates , 1988, Brain Research.
[184] G. Hanson,et al. Differences in the central serotonergic effects of Methylenedioxymethamphetamine (MDMA) in mice and rats , 1987, Neuropharmacology.
[185] G. Ricaurte,et al. Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery , 1999, The Journal of Neuroscience.
[186] E. Azmitia,et al. MDMA (Ecstasy) Inhibition of MAO Type A and Type B: Comparisons with Fenfluramine and Fluoxetine (Prozac) , 1994, Neuropsychopharmacology.
[187] John Hilton,et al. Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .
[188] G. Hanson,et al. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. , 1987, European journal of pharmacology.
[189] B. Yamamoto,et al. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. , 1995, The Journal of pharmacology and experimental therapeutics.
[190] Charles R. Ashby Jr.,et al. The Effect of the Repeated Administration of the Compound 3,4-Methylenedioxymethamphetamineon the Response of Rats to the5-HT2A,C Receptor Agonist (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) , 1997, Neuropsychobiology.
[191] W. Slikker,et al. Acute Effects of Dexfenfluramine (d‐FEN) and Methylenedioxymethamphetamine (MDMA) before and after Short‐Course, High‐Dose Treatment , 1998, Annals of the New York Academy of Sciences.
[192] A. Freemont,et al. Ecstasy, 3–4 Methylenedioxymethamphetamine (MDMA), a Fatality Associated with Coagulopathy and Hyperthermia , 1991, Journal of the Royal Society of Medicine.
[193] M. Geyer,et al. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. , 1990, The Journal of pharmacology and experimental therapeutics.
[194] B. Yamamoto,et al. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3, 4-methylenedioxymethamphetamine , 1992, Brain Research.
[195] A. Yacobi,et al. Toxicokinetics and New Drug Development , 1989 .
[196] R. de la Torre,et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. , 1999, The Journal of pharmacology and experimental therapeutics.
[197] J. Docherty,et al. Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. , 1999, British Journal of Pharmacology.
[198] J L Katz,et al. Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. , 1993, The Journal of pharmacology and experimental therapeutics.
[199] F. Schifano. Chronic atypical psychosis associated with MDMA ("ecstasy") abuse , 1991, The Lancet.
[200] R. de la Torre,et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.
[201] A. Scholey,et al. Subjective ratings of prospective memory deficits in MDMA (‘ecstasy’) users , 2001, Human psychopharmacology.
[202] W. Slikker,et al. Peroxynitrite plays a role in methamphetamine‐induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper–zinc superoxide dismutase , 2001, Journal of neurochemistry.
[203] M. Colado,et al. A study of the mechanism of MDMA (‘Ecstasy’)‐induced neurotoxicity of 5‐HT neurones using chlormethiazole, dizocilpine and other protective compounds , 1994, British journal of pharmacology.
[204] U. McCann,et al. Evidence against an essential role of endogenous brain dopamine in methamphetamine‐induced dopaminergic neurotoxicity , 2001, Journal of neurochemistry.
[205] S. Kish. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? , 2002, Pharmacology Biochemistry and Behavior.
[206] J. Krystal,et al. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? , 1992, The American journal of drug and alcohol abuse.
[207] G. Hanson,et al. Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. , 1989, European journal of pharmacology.
[208] F. Peters,et al. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). , 2000, Toxicology letters.
[209] H. J. Olverman,et al. Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the dark agouti rat , 2004, Psychopharmacology.
[210] R. T. Miller,et al. 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. , 1997, European journal of pharmacology.
[211] F. Carvalho,et al. Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature , 2002, Archives of Toxicology.
[212] P. Milligan,et al. Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. , 1999, Clinical chemistry.
[213] R. Dafters,et al. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) but not by fenfluramine , 1998, Psychopharmacology.
[214] J. Nash,et al. Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. , 1991, European journal of pharmacology.
[215] V. Höllt,et al. Acute injection of drugs with low addictive potential (delta(9)-tetrahydrocannabinol, 3,4-methylenedioxymethamphetamine, lysergic acid diamide) causes a much higher c-fos expression in limbic brain areas than highly addicting drugs (cocaine and morphine). , 1999, Brain research. Molecular brain research.
[216] M. Shankaran,et al. Effect of 3,4-Methylenedioxymethamphetamine (MDMA) on Hippocampal Dopamine and Serotonin , 1998, Pharmacology Biochemistry and Behavior.
[217] M. Colado,et al. 5‐HT loss in rat brain following 3, 4‐methylenedioxymethamphetamine (MDMA), p‐chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine , 1993, British journal of pharmacology.
[218] A. Romano,et al. Methylenedioxyamphetamine: neurotoxic effects on serotonergic projections to brainstem nuclei in the rat , 1993, Brain Research.
[219] B. Yamamoto,et al. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. , 1988, European journal of pharmacology.
[220] M. Colado,et al. In vivo evidence for free radical involvement in the degeneration of rat brain 5‐HT following administration of MDMA (‘ecstasy’) and p‐chloroamphetamine but not the degeneration following fenfluramine , 1997, British journal of pharmacology.
[221] W. Hall,et al. Recreational MDMA use in Sydney: a profile of 'Ecstacy' users and their experiences with the drug. , 1992, British journal of addiction.
[222] K. Hashimoto,et al. 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-induced egr-1 mRNA in rat brain: pharmacological manipulation. , 2000, European journal of pharmacology.
[223] M. Colado,et al. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA (‘ecstasy’) on the 5-HT and dopamine concentrations in mouse brain , 2001, Neuropharmacology.
[224] Z. Szabo,et al. Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). , 2000, Toxicology letters.
[225] C. Piantadosi,et al. Brain Temperature Alters Hydroxyl Radical Production during Cerebral Ischemia/Reperfusion in Rats , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[226] S. Dawling,et al. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") , 1992, The Lancet.
[227] W. Slikker,et al. Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. , 1995, Neurotoxicology and teratology.
[228] M. Shankaran,et al. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration , 1999, Psychopharmacology.
[229] T. Ziporyn. A growing industry and menace: makeshift laboratory's designer drugs. , 1986, JAMA.
[230] F. Vollenweider,et al. Localization of MDMA‐induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA) , 2001, Human brain mapping.
[231] E. D. De Souza,et al. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4‐methylenedioxymethamphetamine): Assessment using quantitative autoradiography , 1991, Synapse.
[232] G. Ricaurte,et al. Effect of 7‐nitroindazole on body temperature and methamphetamine‐induced dopamine toxicity , 1998, Neuroreport.
[233] R. Foltz,et al. Ion trap tandem mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine. , 1991, Chemical research in toxicology.
[234] M. Varela-Rey,et al. 3,4-Methylenedioxymethamphetamine (“Ecstasy”) Stimulates the Expression of α1(I) Procollagen mRNA in Hepatic Stellate Cells , 1999 .
[235] T. Alexander,et al. CHARACTERIZATION OF THREE NEW PSYCHOTOMIMETICS , 1978 .
[236] L. D. Reid,et al. Naltrindole, a δ-opioid antagonist, blocks MDMA's ability to enhance pressing for rewarding brain stimulation , 1996, Pharmacology Biochemistry and Behavior.
[237] J. Kelly,et al. 3,4‐methylenedioxymethamphetamine (MDMA; Ecstasy) administration produces dose‐dependent neurochemical, endocrine and immune changes in the rat , 1999 .
[238] M. Geyer,et al. Effects of MDMA (Ecstasy) on Prepulse Inhibition and Habituation of Startle in Humans after Pretreatment with Citalopram, Haloperidol, or Ketanserin , 2001, Neuropsychopharmacology.
[239] H. Sackeim,et al. Serotonin, cerebral blood flow, and cerebral metabolic rate in geriatric major depression and normal aging , 1999, Brain Research Reviews.
[240] K. Varner,et al. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. , 2002, The Journal of pharmacology and experimental therapeutics.
[241] Rodney J. Croft,et al. The relative contributions of ecstasy and cannabis to cognitive impairment , 2001, Psychopharmacology.
[242] J. del Río,et al. MDMA ('Ecstasy') enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. , 1998, European journal of pharmacology.
[243] J. O'Callaghan,et al. Chronic treatment with supraphysiological levels of corticosterone enhances d-MDMA-induced dopaminergic neurotoxicity in the C57BL/6J female mouse , 2002, Brain Research.
[244] J. Robinson,et al. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? , 2001, Psychopharmacology.
[245] Z. Szabo,et al. Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.
[246] M. Chance. Aggregation as a factor influencing the toxicity of sympathomimetic amines in mice. , 1946, The Journal of pharmacology and experimental therapeutics.
[247] U. McCann,et al. MDMA (“Ecstasy”) and panic disorder: Induction by a single dose , 1992, Biological Psychiatry.
[248] E. Walderhaug,et al. Lowering of serotonin by rapid tryptophan depletion increases impulsiveness in normal individuals , 2002, Psychopharmacology.
[249] D. Charney,et al. The effect of IV l-tryptophan on prolactin, growth hormone, and mood in healthy subjects , 2004, Psychopharmacology.
[250] G. Griebel. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. , 1995, Pharmacology & therapeutics.
[251] J. Fisk,et al. Working memory deficits in current and previous users of MDMA ('ecstasy'). , 2000, British journal of psychology.
[252] A. Winstock. Chronic paranoid psychosis after misuse of MDMA. , 1991, BMJ.
[253] H. Curran,et al. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. , 1997, Addiction.
[254] D. Cannon,et al. In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3,4-methylenedioxymethamphetamine. , 2002, European journal of pharmacology.
[255] Beth Borowsky,et al. Trace amines: Identification of a family of mammalian G protein-coupled receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[256] A. Somogyi,et al. Acute Toxicity of 3,4-Methylenedioxymethamphetamine (MDMA) in Sprague–Dawley and Dark Agouti Rats , 1999, Pharmacology Biochemistry and Behavior.
[257] A. Winstock,et al. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. , 2001, Drug and alcohol dependence.
[258] M. Farré,et al. Pharmacology of MDMA in Humans , 2000, Annals of the New York Academy of Sciences.
[259] M. Forsling,et al. Arginine vasopressin release in response to the administration of 3,4‐methylenedioxymethamphetamine (“ecstasy”): is metabolism a contributory factor? , 2001, The Journal of pharmacy and pharmacology.
[260] J. Vetulani,et al. Enhancement of responsiveness of the central serotonergic system and serotonin-2 receptor density in rat frontal cortex by electroconvulsive treatment. , 1981, European journal of pharmacology.
[261] F. Vollenweider,et al. Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans , 2000, Neuropsychopharmacology.
[262] A. Parrott,et al. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. , 2000, Drug and alcohol dependence.
[263] U. McCann,et al. Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) , 1996, Drug safety.
[264] S. Peroutka,et al. Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat , 1989, Neuroscience Letters.
[265] C. Marsden,et al. Protection against 3,4‐methylenedioxymethamphetamine‐induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia , 2002, Journal of Neurochemistry.
[266] S. Peroutka,et al. Neurochemistry and Neurotoxicity of 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”) , 1990, Journal of neurochemistry.
[267] J. Fitzgerald,et al. Sympathomimetic Actions of Methylenedioxymethamphetamine in Rat and Rabbit Isolated Cardiovascular Tissues , 1994, The Journal of pharmacy and pharmacology.
[268] L. Seiden,et al. Reserpine attenuates d-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis , 1998, Brain Research.
[269] G. Marek,et al. The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat , 1990, Brain Research.
[270] T. Monks,et al. Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. , 1999, Chemical research in toxicology.
[271] L. Itti,et al. Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study , 2000, Psychiatry Research: Neuroimaging.
[272] B. Rumack,et al. Methylenedioxyamphetamine. Clinical description of overdose, death, and review of pharmacology. , 1981, Archives of internal medicine.
[273] R. Foltz,et al. In vivo formation of aromatic hydroxylated metabolites of 3,4-(methylenedioxy)methamphetamine in the rat: identification by ion trap tandem mass spectrometric (MS/MS and MS/MS/MS) techniques. , 1991, Biological mass spectrometry.
[274] P. Kelly,et al. Alcohol and drug use in UK university students , 1996, The Lancet.
[275] C. Epstein,et al. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA) , 1994, Brain Research.
[276] C. Hyde,et al. ‘Ecstasy’ Psychosis and Flashbacks , 1991, British Journal of Psychiatry.
[277] S. Yeh. N‐tert‐butyl‐alpha‐phenylnitrone protects against 3,4‐methylenedioxymethamphetamine‐induced depletion of serotonin in rats , 1999, Synapse.
[278] D. Stein,et al. Effects of "Ecstasy" blocked by serotonin reuptake inhibitors. , 1999, The Journal of clinical psychiatry.
[279] C. Kornetsky,et al. The threshold lowering effects of MDMA (ecstasy) on brain-stimulation reward , 2004, Psychopharmacology.
[280] G. Hanson,et al. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. , 1988, The Journal of pharmacology and experimental therapeutics.
[281] E. Gouzoulis-Mayfrank,et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) , 2000, Journal of neurology, neurosurgery, and psychiatry.
[282] G. Michell,et al. Effect of bupropion on chocolate craving. , 1989, The American journal of psychiatry.
[283] M. Morgan,et al. Ecstasy (MDMA): a review of its possible persistent psychological effects , 2000, Psychopharmacology.
[284] M. Colado,et al. A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long term defect in thermoregulation , 2001, Psychopharmacology.
[285] K. Rice,et al. Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin , 2001, Synapse.
[286] R. T. Miller,et al. Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. , 1996, Chemical research in toxicology.
[287] H. J. Olverman,et al. Effects of ecstasy on aldosterone secretion in the rat in vivo and in vitro. , 1996, Endocrine research.
[288] A. Green. Clomethiazole (Zendra) in acute ischemic stroke: basic pharmacology and biochemistry and clinical efficacy. , 1998, Pharmacology & therapeutics.
[289] S. Biello,et al. MDMA and fenfluramine alter the response of the circadian clock to a serotonin agonist in vitro , 2001, Brain Research.
[290] J. Kehne,et al. Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats. , 1992, The Journal of pharmacology and experimental therapeutics.
[291] M. Rattray. Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. , 1991, Essays in biochemistry.
[292] W. Slikker,et al. Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine. , 1994, The Journal of pharmacology and experimental therapeutics.
[293] B. Yamamoto,et al. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. , 1994, European journal of pharmacology.
[294] T. Kameyama,et al. The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats , 1989, Pharmacology Biochemistry and Behavior.
[295] G. Ricaurte,et al. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. , 1992, The Journal of pharmacology and experimental therapeutics.
[296] Y. Itzhak,et al. Effects of 7-nitroindazole, an NOS inhibitor on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in mice. , 1998, Annals of the New York Academy of Sciences.
[297] L. Reneman,et al. The Acute and Chronic Effects of MDMA (“Ecstasy”) on Cortical 5-HT2A Receptors in Rat and Human Brain , 2002, Neuropsychopharmacology.
[298] N. Salansky,et al. Responses of the Nervous System to Low Frequency Stimulation and EEG Rhythms: Clinical Implications , 1998, Neuroscience & Biobehavioral Reviews.
[299] F. Vollenweider,et al. Acute psychological and physiological effects of MDMA (“Ecstasy”) after haloperidol pretreatment in healthy humans , 2000, European Neuropsychopharmacology.
[300] J. Kelly,et al. Some behavioural and neurochemical aspects of subacute (±)3,4-methylenedioxymethamphetamine administration in rats , 1995, Pharmacology Biochemistry and Behavior.
[301] B. Yamamoto,et al. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. , 1999, European journal of pharmacology.
[302] S. Bhattacharya,et al. Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy): An experimental study , 1998 .
[303] G. Battaglia,et al. MDMA Effects in Brain: Pharmacologic Profile and Evidence of Neurotoxicity from Neurochemical and Autoradiographic Studies , 1990 .
[304] B. Sahakian,et al. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users , 2002, Psychopharmacology.
[305] S. Peroutka,et al. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[306] U. McCann,et al. Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users. , 1991, Journal of clinical psychopharmacology.
[307] M. Geyer,et al. Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans , 1999, Psychopharmacology.
[308] F. Vollenweider,et al. Caveat Emptor: Editors Beware , 2001, Neuropsychopharmacology.
[309] M. Geyer,et al. Characterization of the Disruptions of Prepulse Inhibition and Habituation of Startle Induced by α-Ethyltryptamine , 1997, Neuropsychopharmacology.
[310] U. McCann,et al. Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration , 2002, Psychopharmacology.
[311] J. Secker,et al. A study of the mechanism of insulin , 1925, The Journal of physiology.
[312] J. Powell,et al. Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or ‘ecstasy’: evidence for cognitive impairment , 2001, Psychological Medicine.
[313] Andrew C. Parrott,et al. Ecstasy (MDMA) in Recreational Users: Self‐Reported Psychological and Physiological Effects , 1997 .
[314] G. Gerra,et al. Serotonergic function after (±)3,4‐methylene-dioxymethamphetarnine (‘Ecstasy’) in humans , 1998, International clinical psychopharmacology.
[315] B. Yamamoto,et al. Acute and subchronic effects of methylenedioxymethamphetamine [(±)MDMA] on locomotion and serotonin syndrome behavior in the rat , 1989, Pharmacology Biochemistry and Behavior.
[316] M. Ramírez,et al. Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. , 1999, Neuroreport.
[317] J. McDaid,et al. Vascular actions of MDMA involve α1 and α2‐adrenoceptors in the anaesthetized rat , 2001 .
[318] M. Titeler,et al. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. , 1987, Molecular pharmacology.
[319] Green Ar. Clomethiazole (Zendra®) in Acute Ischemic Stroke: Basic Pharmacology and Biochemistry and Clinical Efficacy , 1998 .
[320] J. Burn. REVIEW OF PHARMACOLOGY , 1961 .
[321] J. Kehne,et al. 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats , 1996, Psychopharmacology.
[322] R. Dafters. Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”) in rats , 1994, Psychopharmacology.
[323] P. O'cain,et al. Cardiovascular and sympathetic responses and reflex changes elicited by MDMA , 2000, Physiology & Behavior.
[324] Peroutka Sj. Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. , 1987 .
[325] Patrick M. O'Malley,et al. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2004. , 2003 .
[326] D. Dietrich,et al. Emotion/cognition-coupling in word recognition memory of depressive patients: an event-related potential study , 2000, Psychiatry Research.
[327] A. Forrest,et al. Pathology of deaths associated with "ecstasy" and "eve" misuse. , 1996, Journal of clinical pathology.
[328] K. Cunningham,et al. Pharmacological Studies of the Acute Effects of (+)-3,4-Methylenedioxymethamphetamine on Locomotor Activity: Role of 5-HT1B/1D and 5-HT2 Receptors , 2002, Neuropsychopharmacology.
[329] S. Yeh. Effects of Salicylate on 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Neurotoxicity in Rats , 1997, Pharmacology Biochemistry and Behavior.
[330] H. Wechsler,et al. Increasing MDMA use among college students: results of a national survey. , 2002, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[331] M. Colado,et al. The pharmacology of the acute hyperthermic response that follows administration of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats , 2002, British journal of pharmacology.
[332] Diane B Miller,et al. Restraint as a stressor in mice: Against the dopaminergic neurotoxicity of d-MDMA, low body weight mitigates restraint-induced hypothermia and consequent neuroprotection , 2000, Brain Research.
[333] D. Grahame-Smith. STUDIES IN VIVO ON THE RELATIONSHIP BETWEEN BRAIN TRYPTOPHAN, BRAIN 5‐HT SYNTHESIS AND HYPERACTIVITY IN RATS TREATED WITH A MONOAMINE OXIDASE INHIBITOR AND L‐TRYPTOPHAN , 1971, Journal of neurochemistry.
[334] R. Vaughan,et al. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. , 1998, European journal of pharmacology.
[335] G. Hanson,et al. Body temperature effect on methylenedioxymethamphetamine-induced acute decrease in tryptophan hydroxylase activity. , 1995, European journal of pharmacology.
[336] L. Seiden,et al. Small Changes in Ambient Temperature Cause Large Changes in 3,4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonin Neurotoxicity and Core Body Temperature in the Rat , 1998, The Journal of Neuroscience.
[337] P. McGuire,et al. Diversity of Psychopathology Associated with use of 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) , 1994, British Journal of Psychiatry.
[338] I. McGregor,et al. (+/-)-3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats. , 2000, European journal of pharmacology.
[339] Y. Claustre,et al. Anorectic activities of serotonin uptake inhibitors: correlation with their potencies at inhibiting serotonin uptake in vivo and 3H-mazindol binding in vitro. , 1988, Life sciences.
[340] W. Lovenberg,et al. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. , 1987, Biochemical pharmacology.
[341] I. McGregor,et al. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). , 2001, European journal of pharmacology.
[342] B. Yamamoto,et al. Enhancement of 3,4‐methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate , 2001, Journal of neurochemistry.
[343] Yiwen Zheng,et al. Role of brain nitric oxide in (±)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats 1 Part of the work in this paper has been published as an abstract at 14th Australasian Winter Conference on Brain Research, Sept. 1996. 1 , 1998, Brain Research.
[344] C. J. Schmidt,et al. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. , 1990, European journal of pharmacology.
[345] Z. Szabo,et al. In vivo detection of short‐ and long‐term MDMA neurotoxicity—a positron emission tomography study in the living baboon brain , 1998, Synapse.
[346] G. Ricaurte,et al. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[347] M. Geyer,et al. Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4-methylenedioxyamphetamine (MDEA) in the rat. , 1989, European journal of pharmacology.
[348] J. O'Callaghan,et al. d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity , 2002, Brain Research.
[349] O. Steward,et al. A cellular mechanism for targeting newly synthesized mRNAs to synaptic sites on dendrites , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[350] P. Mcguire,et al. Chronic paranoid psychosis after misuse of MDMA ("ecstasy") , 1991, BMJ.
[351] H N Wagner,et al. Positron Emission Tomography of 5-HT Transporter Sites in the Baboon Brain with [11C]McN5652 , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[352] J. Langston,et al. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration , 1988, Brain Research.
[353] R. Bost,et al. 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. , 1987, JAMA.
[354] R. Dafters. Hyperthermia following MDMA administration in rats: Effects of ambient temperature, water consumption, and chronic dosing , 1995, Physiology & Behavior.
[355] M. Bourin,et al. 3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans , 1999, Neuroscience & Biobehavioral Reviews.
[356] J A Gunn,et al. The action of some amines related to adrenaline. Cyclohexylalkylamines , 1940, The Journal of physiology.
[357] Y. Sugimoto,et al. Involvement of serotonergic and dopaminergic mechanisms in hyperthermia induced by a serotonin-releasing drug, p-chloroamphetamine in mice. , 2001, European journal of pharmacology.
[358] T. Ernst,et al. Cerebral 1H MRS alterations in recreational 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) users , 1999, Journal of magnetic resonance imaging : JMRI.
[359] J. Navarro,et al. MDMA ("ecstasy") exhibits an anxiogenic-like activity in social encounters between male mice. , 2001, Pharmacological research.
[360] W. van den Brink,et al. Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]β-CIT SPECT study – preliminary report , 2001, Psychopharmacology.
[361] U. McCann,et al. Neurotoxic Amphetamine Analogues: Effects in Monkeys and Implications for Humans a , 1992, Annals of the New York Academy of Sciences.
[362] S. Butcher,et al. Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat , 1999, Psychopharmacology.
[363] W. Lovenberg,et al. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. , 1986, European journal of pharmacology.
[364] W. Slikker,et al. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). , 1988, Toxicology and applied pharmacology.
[365] H. Hardman,et al. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. , 1973, Toxicology and applied pharmacology.
[366] C. Epstein,et al. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn‐superoxide dismutase transgenic mice , 1995, Synapse.
[367] B. Yamamoto,et al. Mazindol Attenuates the 3,4‐Methylenedioxymethamphetamine‐Induced Formation of Hydroxyl Radicals and Long‐Term Depletion of Serotonin in the Striatum , 1999, Journal of neurochemistry.
[368] G. Hanson,et al. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat , 1987, Neuropharmacology.
[369] G. Gerra,et al. Long-lasting effects of (±)3,4-methylene-dioxymethamphetamine (Ecstasy) on serotonin system function in humans , 2000, Biological Psychiatry.
[370] D. Richard,et al. Fenfluramine-induced activation of the immediate-early gene c-fos in the striatum: possible interaction between serotonin and dopamine. , 1996, Brain Research. Molecular Brain Research.
[371] P. McGuire. Long term psychiatric and cognitive effects of MDMA use. , 2000, Toxicology letters.
[372] Klaus P. Ebmeier,et al. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users , 1999, British Journal of Psychiatry.
[373] L S Seiden,et al. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.
[374] N. Saunders. No evidence of neurotoxicity exists , 1996, BMJ.
[375] N. Newberry,et al. Characterisation of Human 5‐Hydroxytryptamine2A and 5‐Hydroxytryptamine2C Receptors Expressed in the Human Neuroblastoma Cell Line SH‐SY5Y: Comparative Stimulation by Hallucinogenic Drugs , 1996, Journal of neurochemistry.
[376] E. Meririnne,et al. The Acute Effects of Amphetamine Derivatives on Extracellular Serotonin and Dopamine Levels in Rat Nucleus Accumbens , 1998, Pharmacology Biochemistry and Behavior.
[377] P. Soubrié. Reconciling the role of central serotonin neurons in human and animal behavior , 1986, Behavioral and Brain Sciences.
[378] T. Obradović,et al. Repeated exposure to methylenedioxymethamphetamine (MDMA) alters nucleus accumbens neuronal responses to dopamine and serotonin , 1998, Brain Research.
[379] C. J. Schmidt,et al. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. , 1987, The Journal of pharmacology and experimental therapeutics.
[380] Charles R. Ashby Jr.,et al. Effect of the Repeated Administration of (±)-3,4-Methylenedioxymethamphetamine on the Behavioral Response of Rats to the 5-HT1A Receptor Agonist (±)-8-Hydroxy-(di-n-Propylamino)Tetralin , 2001, Neuropsychobiology.
[381] T. Monks,et al. Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. , 2001, Chemical research in toxicology.
[382] U. McCann,et al. Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence. , 1993, Journal of clinical psychopharmacology.
[383] K. Hashimoto,et al. Induction of Fos protein by 3,4‐ methylenedioxymethamphetamine (Ecstasy) in rat brain: regional differences in pharmacological manipulation , 1997, Addiction biology.
[384] G. N. RUTTY,et al. The pathology of the ring‐substituted amphetamine analogue 3,4‐methylenedioxymethylamphetamine (MDMA, ‘Ecstasy’) , 1997, The Journal of pathology.
[385] D. Jackson,et al. Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation , 1997, Brain Research.
[386] I. McGregor,et al. On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA , 2002, Psychopharmacology.
[387] G. Koob,et al. Methysergide potentiates the hyperactivity produced by MDMA in rats , 1988, Pharmacology Biochemistry and Behavior.
[388] A. Cho,et al. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. , 1996, Biochemical pharmacology.
[389] R. Fitzgerald,et al. Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. , 1990, Chirality.
[390] M. Colado,et al. Studies on the neuroprotective effect of pentobarbitone on MDMA-induced neurodegeneration , 1999, Psychopharmacology.
[391] F. Vollenweider,et al. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies , 2001, Human psychopharmacology.
[392] M. Paule,et al. Effects of MDMA on Complex Brain Function in Laboratory Animals , 1997, Neuroscience & Biobehavioral Reviews.
[393] A. McGregor,et al. Evidence for 5-hydroxytryptamine1A receptor involvement in the control of prolactin secretion in man , 1995, Psychopharmacology.
[394] E. D. De Souza,et al. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.
[395] D M Bronstein,et al. Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. , 1995, The Journal of pharmacology and experimental therapeutics.
[396] L. Seiden,et al. Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys , 1989, Brain Research.
[397] J. Docherty,et al. Effects of methylenedioxymethamphetamine on noradrenaline-evoked contractions of rat right ventricle and small mesenteric artery. , 2001, European journal of pharmacology.
[398] W. Slikker,et al. Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: protective effects of peroxynitrite decomposition catalyst , 1999, Brain Research.
[399] Liesbeth Reneman,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[400] D. Nichols,et al. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. , 1995, The Journal of pharmacology and experimental therapeutics.
[401] J. Mørland,et al. Toxicity of drug abuse--amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. , 2000, Toxicology letters.
[402] M. Molliver,et al. Dual serotoninergic projections to forebrain in the rat: Morphologically distinct 5‐HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives , 1991, The Journal of comparative neurology.
[403] M. Pende,et al. Does GFAP mRNA and mitochondrial benzodiazepine receptor binding detect serotonergic neuronal degeneration in rat? , 1994, Brain Research Bulletin.
[404] Beryl M. Askew. Amphetamine Toxicity in Aggregated Mice , 1961, The Journal of pharmacy and pharmacology.
[405] M. Wilson,et al. Neurotoxicity of MDMA and Related Compounds: Anatomic Studies a , 1990, Annals of the New York Academy of Sciences.
[406] I. McGregor,et al. Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. , 2002, European journal of pharmacology.
[407] J. Kehne,et al. Neurotoxicity of MDMA: Neurochemical Effects , 1990, Annals of the New York Academy of Sciences.
[408] L. Steranka,et al. Effect of cysteine on the persistent depletion of brain monoamines by amphetamine, p-chloroamphetamine and MPTP. , 1987, European journal of pharmacology.
[409] J. Hall,et al. A BEHAVIOURAL AND BIOCHEMICAL STUDY IN RATS OF 5‐HYDROXYTRYPTAMINE RECEPTOR AGONISTS AND ANTAGONISTS, WITH OBSERVATIONS ON STRUCTURE‐ACTIVITY REQUIREMENTS FOR THE AGONISTS , 1981, British journal of pharmacology.
[410] A. Lees,et al. Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits , 1998, Journal of psychopharmacology.
[411] G. D. den Heeten,et al. Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (Ecstasy) users: preliminary results. , 2002, AJNR. American journal of neuroradiology.
[412] Patrick J. O'Donnell,et al. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence , 1999, Psychopharmacology.
[413] R. T. Miller,et al. Metabolism of 5-(glutathion-S-yl)-alpha-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. , 1995, Chemical research in toxicology.
[414] A. Andrews,et al. Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy) , 1999, Neuroscience.
[415] T. Aronson,et al. "Ecstasy" (MDMA)-induced panic. , 1989, The American journal of psychiatry.
[416] John P. Kelly,et al. Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the wistar rat , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[417] W. Slikker,et al. Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. , 1989, Neurotoxicology.
[418] J. Fountain,et al. Adverse effects of stimulant drugs in a community sample of drug users. , 1997, Drug and alcohol dependence.
[419] J. Kelly,et al. Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. , 2001, Life sciences.
[420] W. Slikker,et al. Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats. , 1991, Neurotoxicology and teratology.
[421] S. Peroutka. Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. , 1987, The New England journal of medicine.
[422] G. Battaglia,et al. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[423] M. Colado,et al. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (`ecstasy') , 1998, Neuropharmacology.
[424] J. O'Callaghan,et al. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. , 1994, The Journal of pharmacology and experimental therapeutics.
[425] L. Parsons,et al. Functional Consequences of Repeated (±)3,4-Methylenedioxymethamphetamine (MDMA) Treatment in Rhesus Monkeys , 2001, Neuropsychopharmacology.
[426] J. Richards,et al. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. , 1996, The Journal of pharmacology and experimental therapeutics.
[427] G. Gudelsky,et al. Carrier‐Mediated Release of Serotonin by 3,4‐Methylenedioxymethamphetamine: Implications for Serotonin‐Dopamine Interactions , 1996, Journal of neurochemistry.
[428] G. Goodwin,et al. Ecstasy and neurodegeneration , 1996, BMJ.